Last Updated: 09 Nov 2024
Executive Summary
Hologic Inc. (HOLX), a medical technology company focused on women's health, has a strong financial performance with a market capitalization of $18.29 billion. Its key financial metrics indicate profitability, with an EBITDA of $1.24 billion and EPS of $3.3. However, the company does not currently pay dividends. Analysts are generally positive, with 5 Strong Buy and 6 Buy ratings.
Company Overview
Hologic Inc. provides medical devices for diagnostics, surgery, and medical imaging. It operates in the X-RAY APPARATUS & TUBES & RELATED IRRADIATION APPARATUS industry within the LIFE SCIENCES sector. The company's products are used in various healthcare settings, including hospitals, clinics, and physician offices.
Fundamental Analysis
Revenue: Hologic's revenue for the trailing twelve months (TTM) is $3.99 billion, with a quarterly growth rate of 0.045% year-over-year.
Earnings: The company's diluted EPS TTM is $3.3, resulting in a trailing PE ratio of 23.87.
Profitability: Hologic has a gross profit margin of 0.623 and an operating margin TTM of 0.244, indicating strong profitability.
Return on Equity: The company's return on equity TTM is 0.139, demonstrating its ability to generate profits from shareholder investments.
Technical Analysis
Price Action: Hologic's stock price has been trading between a 52-week high of $84.67 and a 52-week low of $67.59.
Moving Averages: The 50-day moving average is $81.01, and the 200-day moving average is $77.37, indicating a potential upward trend.
Relative Strength Index (RSI): The RSI is currently around 55, suggesting that the stock is neither overbought nor oversold.
Short Term Outlook
Based on the technical analysis, Hologic's stock price may continue its upward trend in the short term. The stock is trading above both moving averages and has a positive RSI. However, investors should monitor the overall market conditions and any potential news or events that could impact the company's performance.
Long Term Outlook
Analysts are generally positive about Hologic's long-term prospects. The company's strong financial performance, focus on women's health, and innovative products position it well for continued growth. However, investors should consider the competitive nature of the industry and the potential impact of macroeconomic factors on the company's business.
Analyst Recommendations
Strong Buy: 5 analysts
Buy: 6 analysts
Hold: 8 analysts
Sell: 0 analysts
Strong Sell: 0 analysts
The consensus analyst target price is $89.08, indicating a potential upside of 13.2% from the current price of $78.76.
